1150 – Vascular events in patients with type 2 diabetes in the year following initiation of second-line therapy: the DISCOVER study – F. Surmont, H. Chen, J. Cid-Ruzafa, P. Fenici, M.B. Gomes, K. Khunti, S. Pocock, W. Rathmann, M.V. Shestakova, I. Shimomura, F. Tang, H. Watada, L. Ji, N. Hammar, M. Kosiborod, UK, USA, Spain, Brazil, Germany, Russian Federation, Japan, China, Sweden

1151 – Eligibility varies across the 4 sodium-glucose cotransporter-2 inhibitor cardiovascular outcome trials in adults from the Diabetes Collaborative Registry – E.T. Wittbrodt, D. Chamberlain, S.V. Arnold, F. Tang, M. Kosiborod, USA

1152 – Rates of major adverse cardiovascular events and mortality with basal insulin by liraglutide use: a DEVOTE sub-analysis – M.F. Ranthe, K. Brown-Frandsen, S.S. Emerson, S.P. Marso, D.K. McGuire, T.R. Pieber, N.R. Poulter, B. Zinman, R. Grøn, M. Lange, A.C. Moses, P. Örsy, R.E. Pratley, on behalf of the DEVOTE Study Group, Denmark, USA, Austria, UK, Canada

1153 – Liraglutide effects in insulin-treated patients in LEADER – C. Tack, S. Jacob, C. Desouza, S.C. Bain, M.A. Nauck, J. Petrie, N.R. Poulter, R.E. Pratley, H.B. Stegmann, H. Bosch-Traberg, E. Startseva, B. Zinman, LEADER Publication Committee on behalf of the LEADER Trial Investigators, Netherlands, Germany, USA, UK, Denmark, Canada

1154 – Arrhythmias and heart rate increase in the LEADER trial and relation to risk of cardiovascular events – M. Husain, S.C. Bain, J.F. Mann, M.A. Nauck, N. Poulter, F.M. Baeres, B. Goldman, A.B. Thomsen, S. Marso, LEADER Publication Committee on behalf of the LEADER Trial Investigators, Canada, UK, Germany, Denmark, USA

1155 – Effect of liraglutide on cardiovascular outcomes in patients with or without prior heart failure history in LEADER – H.A. Saevereid, M. Husain, S.C. Bain, J.F. Mann, M.A. Nauck, N. Poulter, B. Goldman, A.B. Thomsen, S. Marso, LEADER Publication Committee on behalf of the LEADER Trial Investigators, Denmark, Canada, UK, Germany, USA

1156 – Alogliptin and pioglitazone prevent palmitate-induced apoptosis and autophagy in human cardiac progenitor cells from control but not from type 2 diabetic subjects – R. D’Oria, M. Incalza, C. Caccioppoli, A. Leonardini, R. Schipani, A. Cignarelli, A. Natalicchio, S. Perrini, V. Margari, D. Paparella, L. Laviola, F. Giorgino, Italy

1157 – Platelet reactivity and clinical outcome on prasugrel and ticagrelor in type 2 diabetic patients with acute myocardial infarction: real world single centre experiences – M. Samos, T. Bolek, R. Simonova, I. Skornova, F. Kovar, P. Galajda, P. Kubisz, J. Stasko, M. Mokan, Slovakia